泻白散加味治疗小儿肺热型便秘临床疗效观察

发布时间：2018-09-18 06:52

【摘要】：目的：观察验方泻白散加味治疗小儿肺热型便秘的临床有效性及安全性,初步探讨分析从肺论治小儿便秘的临床实用性,为临床从肺论治小儿便秘提供理论及数据支持,为临床诊疗提供科学参考。方法：通过成都中医药大学附属医院儿科门诊收集符合纳入标准的患儿60例,分为治疗组和对照组各30例,治疗组予以验方泻白散加味口服,对照组予以中成药麻仁丸口服。连续给药2周后,观察记录两组治疗前后情况,收集研究数据进行汇总、整理,经SPSS17.0软件处理,进行统计学描述和分析。结果：1、基线分析：两组患儿在性别、年龄、病程以及主、次症积分等方面无明显差异(P0.05),具有可比性；2、组内对照：治疗组与对照组治疗前后自身组内主症及主症积分比较差异显著(P0.01),次症及次症积分比较具有统计学差异(P0.05)；3、组问对照：两组治疗后组间比较主、次症疗效及疾病总疗效具有显著统计学差异(P0.05)；4、疾病总疗效统计：治疗组临床治愈12例,显效14例,有效3例,无效1例,愈显率86.67%,总有效率96.67%；对照组临床治愈4例,显效11例,有效12例,无效3例,愈显率50.00%,总有效率90.00%。结论：泻白散加味治疗小儿肺热型便秘临床疗效显著,且安全可靠。
[Abstract]:Objective: to observe the clinical efficacy and safety of Xiebai Powder in the treatment of infantile pulmonary heat type constipation, to explore the clinical practicability of treating infantile constipation from lung theory, and to provide theoretical and data support for clinical treatment of infantile constipation from lung theory. To provide scientific reference for clinical diagnosis and treatment. Methods: a total of 60 children were divided into treatment group (n = 30) and control group (n = 30) through pediatric outpatient clinic of affiliated Hospital of Chengdu University of traditional Chinese Medicine. The treatment group was treated with Xiebai Powder orally, and the control group with Chinese patent medicine Maren Pill. After 2 weeks of continuous administration, the two groups were observed and recorded before and after treatment, and the data were collected and sorted out. The data were described and analyzed statistically by SPSS17.0 software. Results: there were no significant differences between the two groups in sex, age, course of disease and scores of major and secondary symptoms (P0.05). 2, control group: before and after treatment between the treatment group and the control group, the scores of main symptoms and main symptoms were significantly different (P0.01), and the scores of secondary symptoms and secondary symptoms were significantly different (P0.05). There was significant difference in the curative effect of secondary symptom and total curative effect of disease (P0.05). The total curative effect of disease was statistically significant. In the treatment group, 12 cases were clinically cured, 14 cases were markedly effective, 3 cases were effective, 1 case was ineffective, the effective rate was 86.67%, and the total effective rate was 96.67%, while in the control group, 4 cases were clinically cured. There were 11 cases of remarkable effect, 12 cases of effective and 3 cases of failure. The effective rate was 50.000.The total effective rate was 90.00g. Conclusion: Xiebai Powder is safe and reliable in the treatment of infantile pulmonary heat constipation.
【学位授予单位】：成都中医药大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R272

【相似文献】